{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'efficacy assessment and by the occurrence of SAEs, will be monitored by the Sponsor on', 'a routine basis.', '8.4.', 'Treatment of Overdose', 'For this study, any dose of IP greater than the prescribed daily dose will be considered an', 'overdose. There is no specific treatment recommended to treat an overdose of IP and the subject', 'should receive treatment directed towards any symptoms manifested.', 'In the event of an overdose, the investigator should:', '1. Contact the Medical Monitor as soon as possible.', '2. Closely monitor the subject for any AE/SAE and laboratory abnormalities.', '3. Document the quantity of the excess dose as well as the duration of the overdose.', 'Decisions regarding dose interruptions or modifications will be made by the investigator in', 'consultation with the Medical Monitor based on the clinical evaluation of the subject.', '8.5.', 'Pharmacokinetics', 'Blood samples of approximately 6 mL will be collected for measurement of plasma', 'concentrations of GB001 as specified in the SoA (see Section 1.3):', 'At Week 4, 12, and 16 visits, PK samples will be collected at pre-dose during the', 'visit. At Week 4 visit, an additional PK sample will be taken at approximately', '2.5 hours post-dose.', 'Subjects will be instructed to take their dose in the morning at their regular dosing', 'time on the day prior to Week 4, 12, and 16 visits and to record the time of dosing', 'on a paper worksheet.', 'Subjects will be instructed not to take the dose in the morning on the day of Week 4,', '12, and 16 visits and bring the dose with them for the visit. Subjects will take the dose', 'in the unit following the pre-dose PK sampling during these 3 visits.', '44', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Drug concentration information that may unblind the study will not be reported to investigative', 'sites or blinded personnel until the study has been unblinded.', '8.6.', 'Pharmacodynamics and Biomarkers', 'Nasal mucosal lining (airway) fluid, blood and urine samples may be collected at the designated', 'times specified in the SoA (see Section 1.3) and may be used for multiple exploratory assays to', 'evaluate the placebo-corrected effect of GB001 on potential target engagement, PD biomarkers', '(eg, Th2 pathway activity, lymphocyte subsets, vitamin D, etc.), safety, tolerability, and efficacy', 'parameters.', 'Residual blood, airway, and urine samples may be stored for additional future assays that may', 'elucidate response to GB001. Samples may be stored at a facility selected by the Sponsor, to', 'enable further analysis of biomarker responses to GB001, for a maximum of 8 years (or', \"according to local regulations) following the last subject's last visit for the study.\", 'For more details on the procedures, please refer to the study specific Laboratory Manual.', '8.6.1.', 'Nasal Biomarker Sample', 'Nasal mucosal lining fluid (airway) sample from one nostril may be collected at the', 'Randomization Visit and longitudinally as designated in the SoA. The same nostril should be', 'used for subsequent collection, where possible. These samples may enable the evaluation of', 'airway changes in the DP2 pathway, Th2 pathway activity, and other markers that may correlate', 'with biological response relating to CRS and/or the action of GB001. Sample collection should', 'avoid use of local anesthetic and any anti-histamine use and should precede the Nasal Endoscopy', '(as indicated).', '8.6.2.', 'Blood Biomarker Analyses', 'Blood samples from peripheral vein(s) may be collected at the Randomization Visit and', 'longitudinally as designated in SoA. These samples may enable the evaluation of peripheral', 'changes in markers (eg, DP2 pathway ligands, Th2 cytokines, and markers of granulocyte', 'activation). For more details of the collection and processing of samples please refer to the', 'Laboratory Manual.', '8.6.3.', 'RNA Transcriptome Research', 'Transcriptome studies may be conducted using capillary electrophoresis, microarray, and/or', 'alternative equivalent technologies, which facilitates the measurement of the relative abundances', 'of thousands of ribonucleic acid (RNA) species resulting in a transcriptome profile for each', 'blood sample. This would enable the evaluation of changes in the Th2 signature that may', 'correlate with biological response relating to CRS and/or the action of GB001. Samples will be', 'collected at the clinic at baseline and at the end of the study. Samples are intended to be collected', 'from all subjects but may not all be analyzed.', '45', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}